Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) - Trial PHRR230203-005387
Access comprehensive clinical trial information for PHRR230203-005387 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp & Dohme (I.A.) LLC and is currently Ongoing. The study focuses on Carcinoma, Non-Small-Cell Lung.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
PHRR230203-005387
Phase 3
Ongoing
Trial Details
Philippine Health Research Registry • PHRR230203-005387
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
Study Focus
Interventional
Sponsor & Location
Merck Sharp & Dohme (I.A.) LLC
Australia;Brazil;Canada;Chile;China;Estonia;Germany;Greece;Israel;Italy;Japan;Latvia;Lithuania;Malay
Timeline & Enrollment
Phase 3
Jul 11, 2023
N/A
ICD-10 Classifications
Carcinoma in situ: Bronchus and lung
Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung
Data Source
Philippine Health Research Registry
PHRR230203-005387
Non-Device Trial